Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.


Journal

Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336

Informations de publication

Date de publication:
Aug 2022
Historique:
revised: 28 04 2022
received: 16 02 2022
accepted: 03 05 2022
pubmed: 25 5 2022
medline: 15 7 2022
entrez: 24 5 2022
Statut: ppublish

Résumé

In the absence of widely accepted criteria, determining when a patient with Parkinson's disease (PD) may benefit from more advanced treatments such as device-aided therapy (DAT) so far remains a matter of physician judgment. This analysis investigates how classification of PD varies across countries relative to measures of disease severity. The OBSERVational, cross-sEctional PD (OBSERVE-PD) study included consecutive patients with PD at centers that offer DATs in 18 countries. In this subgroup analysis, we explore intercountry differences in identification of advanced versus non-advanced PD based on physician's clinical judgment, symptoms assessed using Delphi consensus criteria, use of DAT, motor and non-motor symptoms, and caregiver support. Demographic and clinical characteristics were obtained through review of medical records. Overall, 1342 of 2615 patients (51.3%) were assessed by physicians as having advanced PD. The proportion of patients in different countries identified as having advanced PD (24.4-82.2%) varied. In 15 of 18 countries, a greater proportion of patients with advanced PD, according to select Delphi criteria, were identified by physicians as having advanced PD than with non-advanced PD. There was a wide variability across countries in the proportion of patients with no dyskinesia, disabling dyskinesia, dyskinesia pain, and non-motor symptoms who were identified by physicians as having advanced versus non-advanced PD. The proportion of patients identified with advanced PD symptoms varies widely across countries, despite differences on the patients' profiles, indicating a need for objective diagnostic criteria to help identify patients who may benefit from DAT.

Identifiants

pubmed: 35607843
doi: 10.1111/ane.13648
pmc: PMC9541702
doi:

Substances chimiques

Antiparkinson Agents 0
Drug Combinations 0
Gels 0
Levodopa 46627O600J
Carbidopa MNX7R8C5VO

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-176

Subventions

Organisme : AbbVie

Informations de copyright

© 2022 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.

Références

Neuropsychiatr Dis Treat. 2019 Nov 13;15:3187-3195
pubmed: 32009788
Swiss Med Wkly. 2021 Mar 06;151:w20419
pubmed: 33705561
BMC Neurol. 2022 Jan 28;22(1):41
pubmed: 35090406
Eur Neuropsychopharmacol. 2011 Feb;21(2):180-91
pubmed: 20888737
J Neural Transm (Vienna). 2017 Dec;124(12):1529-1537
pubmed: 29116411
Parkinsonism Relat Disord. 2021 Nov;92:59-66
pubmed: 34695657
Front Hum Neurosci. 2019 Aug 08;13:269
pubmed: 31440150
Parkinsons Dis. 2021 Jan 25;2021:6635618
pubmed: 33564391
Curr Med Res Opin. 2018 Dec;34(12):2063-2073
pubmed: 30016901
J Clin Neurosci. 2013 Jan;20(1):102-6
pubmed: 23098389
J Med Assoc Thai. 2011 Jun;94(6):749-55
pubmed: 21696087
Neurodegener Dis Manag. 2020 Oct;10(5):309-323
pubmed: 32873195
Parkinsonism Relat Disord. 2009 Dec;15(10):728-41
pubmed: 19805000
Health Policy. 2014 Jan;114(1):5-14
pubmed: 24054709
Parkinsonism Relat Disord. 2013 Jun;19(6):628-33
pubmed: 23514630
BMC Neurol. 2019 Apr 2;19(1):50
pubmed: 30940119
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Brain Behav. 2020 Sep;10(9):e01753
pubmed: 32683797
Neuroepidemiology. 2017;48(3-4):131-137
pubmed: 28728161
Pract Neurol. 2014 Oct;14(5):310-22
pubmed: 24699931
Acta Neurol Scand. 2022 Aug;146(2):167-176
pubmed: 35607843
Ideggyogy Sz. 2020 Jul 30;73(7-08):261-268
pubmed: 32750243
Clin Park Relat Disord. 2020 Oct 17;4:100075
pubmed: 34316660

Auteurs

Alfonso Fasano (A)

Edmond J Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON, Canada.
Division of Neurology, University of Toronto, Toronto, ON, Canada.
Krembil Research Institute, Toronto, ON, Canada.

Victor S C Fung (VSC)

Movement Disorders Unit, Westmead Hospital, Westmead, NSW, Australia.
Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Klaus Seppi (K)

Medical University Innsbruck, Innsbruck, Austria.

Zvezdan Pirtosek (Z)

University Medical Center Ljubljana, Ljubljana, Slovenia.

Annamária Takáts (A)

Neurological Clinic of Semmelweis University, Budapest, Hungary.

Ali Alobaidi (A)

AbbVie Inc., North Chicago, IL, USA.

Koray Onuk (K)

AbbVie Inc., North Chicago, IL, USA.

Lars Bergmann (L)

AbbVie Inc., North Chicago, IL, USA.

Juan Carlos Parra (JC)

AbbVie Inc., North Chicago, IL, USA.

Bulent Elibol (B)

Department of Neurology, Hacettepe University Hospitals, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH